» Articles » PMID: 33346069

Metabolic Drivers of Non-alcoholic Fatty Liver Disease

Overview
Journal Mol Metab
Specialty Cell Biology
Date 2020 Dec 21
PMID 33346069
Citations 82
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The incidence of non-alcoholic fatty liver disease (NAFLD) is rapidly increasing worldwide parallel to the global obesity epidemic. NAFLD encompasses a range of liver pathologies and most often originates from metabolically driven accumulation of fat in the liver, or non-alcoholic fatty liver (NAFL). In a subset of NAFL patients, the disease can progress to non-alcoholic steatohepatitis (NASH), which is a more severe form of liver disease characterized by hepatocyte injury, inflammation, and fibrosis. Significant progress has been made over the past decade in our understanding of NASH pathogenesis, but gaps remain in our mechanistic knowledge of the precise metabolic triggers for disease worsening.

Scope Of Review: The transition from NAFL to NASH likely involves a complex constellation of multiple factors intrinsic and extrinsic to the liver. This review focuses on early metabolic events in the establishment of NAFL and initial stages of NASH. We discuss the association of NAFL with obesity as well as the role of adipose tissue in disease progression and highlight early metabolic drivers implicated in the pathological transition from hepatic fat accumulation to steatohepatitis.

Major Conclusions: The close association of NAFL with features of metabolic syndrome highlight plausible mechanistic roles for adipose tissue health and the release of lipotoxic lipids, hepatic de novo lipogenesis (DNL), and disruption of the intestinal barrier in not only the initial establishment of hepatic steatosis, but also in mediating disease progression. Human genetic variants linked to NASH risk to date are heavily biased toward genes involved in the regulation of lipid metabolism, providing compelling support for the hypothesis that NASH is fundamentally a metabolic disease.

Citing Articles

Fecal microbiota transplantation improves hepatic steatosis induced by HFD in a mouse model associated with liver ILC1 regulation and indole-3-carbinol level.

Hou P, Yao Y, Wu Y, Yu H, Qin Y, Yi L Front Nutr. 2025; 12:1500293.

PMID: 40046764 PMC: 11879807. DOI: 10.3389/fnut.2025.1500293.


Liver Metastasis in Cancer: Molecular Mechanisms and Management.

Xu W, Xu J, Liu J, Wang N, Zhou L, Guo J MedComm (2020). 2025; 6(3):e70119.

PMID: 40027151 PMC: 11868442. DOI: 10.1002/mco2.70119.


Risk factor analysis and predictive model construction of lean MAFLD: a cross-sectional study of a health check-up population in China.

Zhu R, Xu C, Jiang S, Xia J, Wu B, Zhang S Eur J Med Res. 2025; 30(1):137.

PMID: 40001266 PMC: 11863909. DOI: 10.1186/s40001-025-02373-1.


The role of metabolic reprogramming in liver cancer and its clinical perspectives.

Lu M, Wu Y, Xia M, Zhang Y Front Oncol. 2024; 14:1454161.

PMID: 39610917 PMC: 11602425. DOI: 10.3389/fonc.2024.1454161.


Associations of dietary sources of antioxidant intake and NAFLD: NHANES 2017-2020 and Mendelian randomization.

Yue Z, Jiang Z, Qian L, Li L, Qi X, Hu K Front Nutr. 2024; 11:1447524.

PMID: 39555193 PMC: 11565937. DOI: 10.3389/fnut.2024.1447524.


References
1.
Jang C, Hui S, Lu W, Cowan A, Morscher R, Lee G . The Small Intestine Converts Dietary Fructose into Glucose and Organic Acids. Cell Metab. 2018; 27(2):351-361.e3. PMC: 6032988. DOI: 10.1016/j.cmet.2017.12.016. View

2.
Uyeda K, Repa J . Carbohydrate response element binding protein, ChREBP, a transcription factor coupling hepatic glucose utilization and lipid synthesis. Cell Metab. 2006; 4(2):107-10. DOI: 10.1016/j.cmet.2006.06.008. View

3.
Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal W, Strowig T . Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature. 2012; 482(7384):179-85. PMC: 3276682. DOI: 10.1038/nature10809. View

4.
Fletcher J, Deja S, Satapati S, Fu X, Burgess S, Browning J . Impaired ketogenesis and increased acetyl-CoA oxidation promote hyperglycemia in human fatty liver. JCI Insight. 2019; 5. PMC: 6629163. DOI: 10.1172/jci.insight.127737. View

5.
Tappy L, Le K, Tran C, Paquot N . Fructose and metabolic diseases: new findings, new questions. Nutrition. 2010; 26(11-12):1044-9. DOI: 10.1016/j.nut.2010.02.014. View